Recent Finacing
Recent Raise
Acelyrin is a late-stage clinical biopharma that acquires, develops, and commercializes drug candidates, holds exclusive global rights to izokibep (via Affibody), and is advancing it in HS and uveitis.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at ACELYRIN.
